| Patient‐Level Characteristics (n = 282) | N (%) | Bridging Episode‐Level Characteristics (n = 1,976) | N (%) |
|---|---|---|---|
| Study Site | Bridging Type | ||
| University of Michigan | 215 (76.2) | UFH | 566 (28.6) |
| Medical College of Wisconsin | 67 (23.8) | LMWH | 1,410 (71.4) |
| Age at time of LVAD implantation | Duration of bridging (in days) | ||
| Median (IQR) | 56 (46–64) | Median (IQR) | 5 (3–9) |
| Type of LVAD | Aspirin dosage | ||
| HeartMate 3 | 67 (23.8) | ≤100 mg daily | 371 (19.6) |
| HeartMate II | 32 (11.4) | >100 mg daily | 1,527 (80.5) |
| Heartware HVAD | 182 (64.8) | ||
| Additional course of bridging administered in 30‐day period | |||
| No | 82 (29.1) | ||
| Yes | 200 (70.9) | ||
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.